vs
FIRST FINANCIAL BANKSHARES INC（FFIN）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是FIRST FINANCIAL BANKSHARES INC的1.3倍（$219.9M vs $164.7M），FIRST FINANCIAL BANKSHARES INC净利率更高（44.5% vs -1.0%，领先45.5%），FIRST FINANCIAL BANKSHARES INC同比增速更快（12.0% vs 2.0%），FIRST FINANCIAL BANKSHARES INC自由现金流更多（$286.0M vs $16.8M），过去两年FIRST FINANCIAL BANKSHARES INC的营收复合增速更高（12.7% vs 8.0%）
第一金融银行股份有限公司（FFIN）是总部位于印第安纳州特雷霍特的区域银行，由第一金融集团运营。它是印第安纳州历史最悠久的全国性银行，在美国全国性银行中历史排名第五，其母公司第一金融集团也是维戈县唯一的上市企业。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
FFIN vs OFIX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $164.7M | $219.9M |
| 净利润 | $73.3M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | 54.4% | 0.2% |
| 净利率 | 44.5% | -1.0% |
| 营收同比 | 12.0% | 2.0% |
| 净利润同比 | 17.6% | 92.4% |
| 每股收益（稀释后） | $0.51 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $164.7M | $219.9M | ||
| Q3 25 | $161.3M | $205.6M | ||
| Q2 25 | $156.6M | $203.1M | ||
| Q1 25 | $149.0M | $193.6M | ||
| Q4 24 | $147.1M | $215.7M | ||
| Q3 24 | $139.5M | $196.6M | ||
| Q2 24 | $134.5M | $198.6M | ||
| Q1 24 | $129.6M | $188.6M |
| Q4 25 | $73.3M | $-2.2M | ||
| Q3 25 | $52.3M | $-22.8M | ||
| Q2 25 | $66.7M | $-14.1M | ||
| Q1 25 | $61.3M | $-53.1M | ||
| Q4 24 | $62.3M | $-29.1M | ||
| Q3 24 | $55.3M | $-27.4M | ||
| Q2 24 | $52.5M | $-33.4M | ||
| Q1 24 | $53.4M | $-36.0M |
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
| Q4 25 | 54.4% | 0.2% | ||
| Q3 25 | 39.2% | -8.3% | ||
| Q2 25 | 52.2% | -7.9% | ||
| Q1 25 | 50.4% | -25.2% | ||
| Q4 24 | 51.7% | -5.3% | ||
| Q3 24 | 48.3% | -9.6% | ||
| Q2 24 | 47.3% | -12.5% | ||
| Q1 24 | 50.0% | -15.6% |
| Q4 25 | 44.5% | -1.0% | ||
| Q3 25 | 32.4% | -11.1% | ||
| Q2 25 | 42.6% | -6.9% | ||
| Q1 25 | 41.2% | -27.4% | ||
| Q4 24 | 42.4% | -13.5% | ||
| Q3 24 | 39.7% | -13.9% | ||
| Q2 24 | 39.0% | -16.8% | ||
| Q1 24 | 41.2% | -19.1% |
| Q4 25 | $0.51 | $-0.05 | ||
| Q3 25 | $0.36 | $-0.57 | ||
| Q2 25 | $0.47 | $-0.36 | ||
| Q1 25 | $0.43 | $-1.35 | ||
| Q4 24 | $0.43 | $-0.76 | ||
| Q3 24 | $0.39 | $-0.71 | ||
| Q2 24 | $0.37 | $-0.88 | ||
| Q1 24 | $0.37 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $450.0M |
| 总资产 | $15.4B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
| Q4 25 | $1.9B | $450.0M | ||
| Q3 25 | $1.8B | $442.5M | ||
| Q2 25 | $1.7B | $458.3M | ||
| Q1 25 | $1.7B | $458.3M | ||
| Q4 24 | $1.6B | $503.1M | ||
| Q3 24 | $1.7B | $525.9M | ||
| Q2 24 | $1.5B | $546.0M | ||
| Q1 24 | $1.5B | $570.3M |
| Q4 25 | $15.4B | $850.6M | ||
| Q3 25 | $14.8B | $832.6M | ||
| Q2 25 | $14.4B | $837.2M | ||
| Q1 25 | $14.3B | $823.1M | ||
| Q4 24 | $14.0B | $893.3M | ||
| Q3 24 | $13.6B | $867.9M | ||
| Q2 24 | $13.2B | $882.0M | ||
| Q1 24 | $13.2B | $906.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $299.4M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $286.0M | $16.8M |
| 自由现金流率自由现金流/营收 | 173.6% | 7.6% |
| 资本支出强度资本支出/营收 | 8.2% | 4.9% |
| 现金转化率经营现金流/净利润 | 4.08× | — |
| 过去12个月自由现金流最近4个季度 | $503.1M | $-1.3M |
8季度趋势，按日历期对齐
| Q4 25 | $299.4M | $27.7M | ||
| Q3 25 | $86.5M | $12.4M | ||
| Q2 25 | $61.3M | $11.6M | ||
| Q1 25 | $76.8M | $-18.4M | ||
| Q4 24 | $309.6M | $23.7M | ||
| Q3 24 | $80.7M | $11.7M | ||
| Q2 24 | $68.8M | $9.0M | ||
| Q1 24 | $75.6M | $-18.6M |
| Q4 25 | $286.0M | $16.8M | ||
| Q3 25 | $83.7M | $2.5M | ||
| Q2 25 | $58.7M | $4.5M | ||
| Q1 25 | $74.7M | $-25.1M | ||
| Q4 24 | $292.9M | $15.2M | ||
| Q3 24 | $77.7M | $6.3M | ||
| Q2 24 | $63.8M | $-360.0K | ||
| Q1 24 | $71.7M | $-29.1M |
| Q4 25 | 173.6% | 7.6% | ||
| Q3 25 | 51.9% | 1.2% | ||
| Q2 25 | 37.5% | 2.2% | ||
| Q1 25 | 50.1% | -13.0% | ||
| Q4 24 | 199.1% | 7.0% | ||
| Q3 24 | 55.7% | 3.2% | ||
| Q2 24 | 47.4% | -0.2% | ||
| Q1 24 | 55.3% | -15.4% |
| Q4 25 | 8.2% | 4.9% | ||
| Q3 25 | 1.7% | 4.8% | ||
| Q2 25 | 1.6% | 3.5% | ||
| Q1 25 | 1.4% | 3.5% | ||
| Q4 24 | 11.4% | 4.0% | ||
| Q3 24 | 2.2% | 2.7% | ||
| Q2 24 | 3.7% | 4.7% | ||
| Q1 24 | 3.0% | 5.6% |
| Q4 25 | 4.08× | — | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 0.92× | — | ||
| Q1 25 | 1.25× | — | ||
| Q4 24 | 4.97× | — | ||
| Q3 24 | 1.46× | — | ||
| Q2 24 | 1.31× | — | ||
| Q1 24 | 1.42× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FFIN
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
